Skip to content
CompletedPhase 1

SPL026 With or Without SSRIs in Participants With MDD

NCT05553691 · Small Pharma Ltd

Closed to entry
Status
Not accepting participants
Phase 1
Phase
18
Target enrolment
2
Study sites
Outside the US

What it is testing

Summary

The main aim of the study is to test the safety and tolerability of single doses of SPL026 (N,N-dimethyltryptamine \[DMT\] fumarate, a psychedelic tryptamine) in patients currently taking a selective serotonin reuptake inhibitor (SSRI) for their depression, but for whom the SSRI is not fully relieving their depression.

Summary as written by the trial’s own sponsor and published on ClinicalTrials.gov API v2. It is the sponsor’s description, reproduced unedited, not an assessment by this site.

What counts as success

Primary outcome measures

  • Safety & tolerability: Adverse Events

    Measured over Screening to End-of-Study Follow-up (Day 29)

  • Safety & tolerability: Lab biochemistry

    Measured over Screening, Day -1 and Day 1

  • Safety & tolerability: Vital signs - Heart Rate

    Measured over Screening to Day 2

  • Safety & tolerability: Vital signs - Blood pressure

    Measured over Screening to Day 2

  • Safety & tolerability: Vital signs - Temperature

    Measured over Screening to Day 2

  • Safety & tolerability: Electrocardiogram

    Measured over Screening to Day 2

  • Safety & tolerability: Suicidal Ideation

    Measured over Screening to End-of-Study Follow-up (Day 29)

A trial succeeds or fails on its primary outcome, declared in advance. Everything else it reports is secondary by definition.

Who can take part

Eligibility, as published

18 Years
Ages
All
Sex
Not accepted
Healthy volunteers
Inclusion Criteria: * MDD diagnosis * Previously tried at least one approved method of treatment for their depression * No monoamine oxidase-inhibitor class antidepressants for at least 3 months * Deemed healthy on the basis of a clinical history, physical examination, ECG, vital signs, laboratory tests of blood and urine * No psychedelic drug use in the 6 months before dosing until the end of the study * Willing to follow the contraception requirements of the trial * Willing to be contacted by email and video call, and have online access * Able to give fully informed written consent * Test Cohort only: currently on a stable dose of an unspecified single SSRI alone and not in combination with any other psychiatric medications, for at least 6 weeks prior to Screening with no intention of making any changes * Control Cohort only: no antidepressant medication for 6 months before dosing Exclusion Criteria: * Substance use disorder * Current or clinically relevant history of a psychotic disorder, or first-degree relatives with a clinically relevant history of a psychotic disorder * Significant history of mania * Significant risk of suicide * Clinically relevant abnormal findings at the screening assessment * Blood pressure, heart rate, or QTcF outside the acceptable ranges * Acute or chronic illness (other than MDD) or infection * Clinically relevant abnormal medical history or concurrent medical condition (other than MDD) * Use of any serotonergic psychedelics within 6 months prior to dosing * Patients of child-bearing potential who are pregnant or lactating, or who are sexually active and not using a reliable method of contraception * History of a severe adverse reaction to any drug or sensitivity to serotonergic psychedelic drugs * Use of over-the-counter or prescribed medication (excluding oral contraceptives, hormone replacement therapy and SSRIs \[Test Cohort only\]) within previous 28 day before dose of trial medication; or paracetamol or ibuprofen within 4 hours prior to dosing

Where

2 study sites

FacilityCityRegionCountry
Mac Clinical ResearchManchesterGreater ManchesterUnited Kingdom
MAC Clinical ResearchLiverpoolPrescotUnited Kingdom

On the registry

Contact the trial directly

This site does not enrol anyone and is not involved in this trial. To ask about taking part, use the sponsor’s own contact details on the official registry record, which is also where the most current version of everything above lives.

Before you do, the preparation checklist lists what a site will ask you on a first call and what is worth asking them. It is free and collects nothing.

NCT05553691 on ClinicalTrials.gov →

Last updated in the registry 2024-06-14. Registry records change; this page reflects the data build of 2026-08-25.

Related

Where this trial sits